Latest Manufacturing Expansion News

Vmoto Limited reported a 10.8% revenue decline to $20.8 million in H1 2025 but reduced its net loss slightly to $3 million, buoyed by resilient international sales and a strategic partnership with Uber to electrify delivery fleets across Europe.

Bioxyne Limited reports a remarkable financial turnaround for FY2025, driven by a 217% revenue surge and its first significant profit, underpinned by expanded medicinal cannabis manufacturing and new supply contracts.

Waterco Limited reported a modest 4% revenue increase for FY25 but saw net profit fall sharply by 31%, weighed down by restructuring and foreign exchange losses. The company maintains its dividend and eyes growth through innovation and regional expansion.

Fluence Corporation Limited reported a robust 64.7% revenue increase to $33.1 million in H1 2025, driven by the Ivory Coast Addendum project and a strategic pivot to high-margin solutions. The company improved EBITDA to a positive $0.1 million and reduced fixed costs, signaling progress in its operational realignment.

SomnoMed delivered a strong FY25 performance with revenue climbing 22% to $111.5 million and EBITDA turning positive at $9.2 million, boosted by operational improvements and FDA clearance of its Rest Assure device. The company projects further growth in FY26 with expanded manufacturing and ongoing innovation.

Sprintex Limited reported a 26% revenue increase for FY25 but also a 37% rise in net loss, as it accelerates global expansion through key distribution deals and manufacturing upgrades.

Nanosonics delivered a robust FY25 with 17% revenue growth and a 72% jump in profit before tax, propelled by next-gen trophon devices and advancing CORIS commercialisation.

PolyNovo Limited reported a robust 28.9% increase in group sales to A$118.6 million for FY25, alongside a 151% surge in net profit after tax to A$13.2 million, driven by strong U.S. growth and key regulatory approvals.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial expansion and strategic investments in R&D and manufacturing. The company confirms full-year guidance while advancing key clinical trials and product launches.

xReality Group has secured a $2.1 million grant from the Australian Government to fast-track AI enhancements in its Operator XR tactical training platform, aiming to solidify its leadership in law enforcement and defense training worldwide.

DroneShield Limited has reported record revenue growth in 2Q25, driven by soaring demand for AI-powered counterdrone solutions amid a global surge in defense spending. The company’s expanding $2.33 billion sales pipeline and strong cash position position it well for future growth.